The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Nimotuzumab plus chemotherapy versus chemotherapy alone in advanced non-small cell lung cancer: A phase II, open-label, multicenter, randomized study.
Kumar Prabhash
No relevant relationships to disclose
Kanaka Govind Babu
No relevant relationships to disclose
Ashok K. Vaid
No relevant relationships to disclose
Ranga Rao Rangaraju
No relevant relationships to disclose
Bhawna Sirohi
No relevant relationships to disclose
Ravi Diwakar
No relevant relationships to disclose
Raghunadha Rao
No relevant relationships to disclose
Madhuchanda Kar
No relevant relationships to disclose
Hemant Malhotra
No relevant relationships to disclose
Shona Milon Nag
No relevant relationships to disclose
Chanchal Goswami
No relevant relationships to disclose
Vinod Raina
No relevant relationships to disclose
Pedapenki Ravi Mohan
No relevant relationships to disclose